Diary - News
All news Valneva Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate
100% seroconversion rate achieved at Day 28 after a single-shot vaccination in a pooled analysis1 of all dose groups
Pooled analysis showed a high antibody response based on geometric mean titre
No serious adverse events or adverse events of special interest were reported up to Day 28
Saint Herblain (France), January 7, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet medical needs, today announced positive Phase 1 interim results for its Chikungunya vaccine candidate, VLA1553. The primary objective of VLA1553-101 Phase 1 study was to assess the overall safety and immunogenicity profile 28 days after a single vaccination across three dose levels.
